Evidence map›Paper›PMID 41545636›Full record

ArticleNPJ digital medicine2026

Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH.

Weiheng Wen, Zenghui Liu, Wenliang Tan, Yingzheng Tan, Wei Li, Jian Wan, Hongsai Hu, Zhengwu Jiang, Xing Tang, Jing Yang and 5 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Weiheng Wen *Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Zenghui Liu *Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Wenliang Tan *Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Yingzheng Tan *Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Wei Li *Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Jian WanTumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Hongsai HuDepartment of Gastroenterology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Zhengwu JiangTumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Xing TangTumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China.
Jing YangDepartment of Gastroenterology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
Jiao XiaoDepartment of Endocrinology, Affiliated Nanhua hospital, University of South China, Hengyang, Hunan, China.
Xiongjin Tan922 Hospital of PLA, Hengyang, Hunan, China.
Xun ChenTumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China. chenxun@csu.edu.cn.
Peili WuDepartment of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. plgeer@163.com.
Yukun LiTumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, Hunan, China. yukun_li@csu.edu.cn.

Funding

Health Research Project of Hunan Provincial Health Commission W20243173Health Research Project of Hunan Provincial Health Commission Z2023100National Natural Science Foundation of China 82300955National Natural Science Foundation of China 82303246Natural Science Foundation of Hunan Province 2023JJ41066Natural Science Foundation of Hunan Province 2025JJ40100Regional Joint Fundation of Guangdong Province 2022A1515111099
6 · The paper itself

Abstract

The progression from metabolic dysfunction-associated steatotic liver disease (MASLD) to metabolic dysfunction-associated steatohepatitis (MASH) is a critical link leading to cirrhosis and hepatocellular carcinoma. Yet the responsible cellular programs remain unclear. We integrated public single-cell, spatial, and bulk transcriptomic datasets to map microenvironmental remodeling and regulatory networks during MASLD-MASH progression. Among the seven major liver cell types identified, monocytes/macrophages and hepatic stellate cells (HSCs) were significantly enriched and demonstrated spatial co-localization within the context of MASH. We identified a DTNA+distinct macrophage subpopulation that was specifically enriched in MASH. This subpopulation exhibited characteristics consistent with M2 polarization, hypoxia, and enhanced inflammatory signaling. Pseudotime trajectory analysis revealed that this state represents a differentiation pathway originating from Kupffer cells to the DTNA+ state. RUNX2 emerged as the key transcriptional regulator. Cell communication analysis demonstrated that DTNA+ macrophages potentially interact with activated HSCs via the RUNX2-PLG-PARD3 axis, contributing to the exacerbation of liver fibrosis. Finally, ensemble machine learning models (mean AUC = 0.839), identified DTNA as the optimal predictive biomarker for distinguishing MASLD from MASH. This study highlight DTNA+ macrophages and the RUNX2-PLG-PARD3 axis as candidate mechanisms and targets for non-invasive diagnosis and therapy in MASH.

Identifiers

PMID41545636
PMCPMC12913776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.